Hakan Demirci, MD
Richard N and Marilyn K Witham Professor of Ophthalmology and Visual Sciences
Professor of Ophthalmology and Visual Sciences
Department of Ophthalmology and Visual Sciences
1000 Wall Street
Ann Arbor, MI 48105
[email protected]

Available to mentor
Hakan Demirci, MD
Professor
  • Qualifications
  • Center Memberships
  • Recent Publications
    • Qualifications
    • Residency
      Henry Ford Hospital, Ophthalmology and Visual Sciences
    Center Memberships
    • Center Member
      Global REACH
    Recent Publications See All Publications
    • Journal Article
      Belzutifan as the first-line treatment for a challenging von Hippel-Lindau-related retinal hemangioblastoma: successful treatment of a case and review of the literature.
      Aykut A, Else T, Demirci H. Can J Ophthalmol, 2024 Dec; 59 (6): e862 - e865. DOI:10.1016/j.jcjo.2024.05.025
      PMID: 39043253
    • Journal Article
      Conjunctival Apocrine Hidrocystoma: A Case Report and Review of Literature.
      Mirzania D, Jacobson A, McHugh J, Demirci H. Cornea, 2024 Nov 1; 43 (11): 1431 - 1435. DOI:10.1097/ICO.0000000000003598
      PMID: 38900714
    • Journal Article
      Epigenetics of Conjunctival Melanoma: Current Knowledge and Future Directions.
      Flick KM, Demirci H, Demirci FY. Cancers (Basel), 2024 Oct 31; 16 (21): DOI:10.3390/cancers16213687
      PMID: 39518125
    • Journal Article
      Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
      Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, Iversen ABB, Kruse A, Jonasch E, Gombos DS, Else T, Demirci H, Maughan BL, Hartnett ME, Coleman HR, Fu W, Perini RF, Liu Y, Linehan WM, Chew EY, LITESPARK-004 Investigator Group - Ocular VHL . Ophthalmology, 2024 Nov; 131 (11): 1324 - 1332. DOI:10.1016/j.ophtha.2024.05.024
      PMID: 38849055
    • Journal Article
      15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
      Harbour JW, Correa ZM, Schefler AC, Mruthyunjaya P, Materin MA, Aaberg TA, Skalet AH, Reichstein DA, Weis E, Kim IK, Fuller TS, Demirci H, Piggott KD, Williams BK, Shildkrot E, Capone A, Oliver SC, Walter SD, Mason J, Char DH, Altaweel M, Wells JR, Duker JS, Hovland PG, Gombos DS, Tsai T, Javid C, Marr BP, Gao A, Decatur CL, Dollar JJ, Kurtenbach S, Zhang S. J Clin Oncol, 2024 Oct; 42 (28): 3319 - 3329. DOI:10.1200/JCO.24.00447
      PMID: 39052972
    • Journal Article
      Establishment and characterization of cMYB-expressing human salivary adenoid cystic carcinoma cell lines (UM-HACC-14, UM-HACC-6) and matching patient-derived xenograft model (UM-PDX-HACC-14).
      Warner KA, Herzog AE, Sahara S, Nör F, Castilho RM, Demirci H, Chepeha DB, Polverini PJ, Nör JE. Oral Surg Oral Med Oral Pathol Oral Radiol, 2024 Oct; 138 (4): 516 - 531. DOI:10.1016/j.oooo.2024.06.005
      PMID: 38971694
    • Journal Article
      Intralesional or intraorbital rituximab injection for the management of biopsy-proven idiopathic orbital inflammation involving the lacrimal gland.
      Demirci H, Ciftci S, Teo HMT, Demirci FY, Shinder R, Elner VM. Can J Ophthalmol, 2024 Oct; 59 (5): e496 - e500. DOI:10.1016/j.jcjo.2023.10.016
      PMID: 37995759
    • Journal Article
      A novel 3D-printed brachytherapy applicator and monte Carlo model for the treatment of conjunctival tumors.
      Matrosic CK, Kronenberg S, Demirci H, Hayman JA, Han H, Lee C. Brachytherapy, 2024 Aug 23; DOI:10.1016/j.brachy.2024.07.004
      PMID: 39181747